Efficacy of trabectedin in patients with advanced or metastatic alveolar soft-part sarcoma

Onkologie

Volumn 35, Issue 5, 2012, Pages 249-252

  Pink, Daniel ^a   Bertz Lepel, Janina ^a   Busemann, Christoph ^b   Bitz, Ulrich ^a   Reichardt, Peter ^a  

^a HELIOS Klinikum Bad Saarow   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

ASPS; Trabectedin

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE; RECOMBINANT ALPHA2B INTERFERON; TOPOTECAN; TRABECTEDIN; TROFOSFAMIDE;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ALVEOLAR SOFT PART SARCOMA; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CHROMOSOME TRANSLOCATION 17; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; DIOXOLES; HUMANS; MALE; MIDDLE AGED; SARCOMA, ALVEOLAR SOFT PART; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862099775     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000338342     Document Type: Article

References (23)

1. Folpe AL, Deyrup AT: Alveolar soft-part sarcoma: a review and update. J Clin Pathol 2006;59:1127-1132.
2. Reichardt P, Lindner T, Pink D, Thuss-Patience PC, Kretzschmar A, Dörken B: Chemotherapy in alveolar soft part sarcomas. What do we know? Eur J Cancer 2003;39:1511-1516.
3. Ladanyi M, Lui MY, Antonescu CR, Krause-Boehm A, Meindl A, Argani P, Healey JH, Ueda T, Yoshikawa H, Meloni-Ehrig A, Sorensen PH, Mertens F, Mandahl N, van den Berghe H, Sciot R, Dal Cin P, Bridge J: The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 2001;20:48-57.
4. Nakanishi K, Araki N, Yoshikawa H, Hashimoto T, Nakamura H: Alveolar soft part sarcoma. Eur Radiol 1998;8:813-816.
5. Portera CA Jr, Ho V, Patel SR, Hunt KK, Feig BW, Respondek PM, Yasko AW, Benjamin RS, Pollock RE, Pisters PW: Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer 2001;91:585-591.
6. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW: DNA sequence-and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996;35: 13303-13309.
7. Zewail-Foote M, Hurley LH: Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 1999;42:2493-2497.
8. Bonfanti M, La Valle E, Fernandez Sousa Faro JM, Faircloth G, Caretti G, Mantovani R, D'Incalci M: Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des 1999;14:179-186.
9. Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y, Kanzaki A, Akiyama SI, Popescu N, Kraemer KH, Pommier Y: Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7:961-966.
10. Erratum in: Nat Med 2001;7:1255.
11. Gajate C, An F, Mollinedo F: Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis. J Biol Chem 2002;277:41580-41589.
12. Sessa C, De Braud F, Perotti A, Bauer J, Curigliano G, Noberasco C, Zanaboni F, Gianni L, Marsoni S, Jimeno J, D'Incalci M, Dall'ó E, Colombo N: Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005;23:1867-1874.
13. Zelek L, Yovine A, Brain E, Turpin F, Taamma A, Riofrio M, Spielmann M, Jimeno J, Misset JL: A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 2006; 94:1610-1614.
14. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gómez J, Park YC, Le Cesne A: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009;27:4188-4196.
15. Dileo P: Trabectedin (T) in metastatic Ewing's family tumors (EFT) patients (pts) progressing after standard chemotherapy. J Clin Oncol 2007; 25(suppl 18s):abstr 10040.
16. Grosso F., et al.: Trabectedin (T) in soft tissue sarcomas (STS) carrying a chromosomal translocation: an exploratory analysis. Proceedings of the 13th Annual Connective Tissue Oncology Society Meeting, Seattle, 2007, abstr 900.
17. Mick R, Crowley JJ, Carroll RJ: Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary end point. Control Clin Trials 2000;21:343-359.
18. Verweij J: Other endpoints in screening studies for soft tissue sarcomas. Oncologist 2008;13(suppl 2):27-31.
19. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
20. Palassini E, Stacchiotti S, Negri T, Brich S, Marrari A, Morosi C, Crippa F, Gronchi A, Pilotti S, Casali PG: Sunitinib malate (SM) in alveolar soft part sarcoma (ASPS). J Clin Oncol 2010;28(suppl 15s):abstr 10014.
21. Gardner K, et al.: Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma. J Clin Oncol 2009; 27(suppl 15s):abstr 10523.
22. Goldberg J, et al.: Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors. J Clin Oncol 2009;27(suppl 15s):abstr 10502.
23. Bani Hani MN, Al Manasra AR: Spontaneous regression in alveolar soft part sarcoma: case report and literature review. World J Surg Oncol 2009;7:53.